The current Beta-thalassemia market is experiencing the emergence of gene therapies as a one-time cure for the patients.
Beta thalassemia is relatively a common heterogeneous autosomal recessive hereditary blood disorder. It is a common form of hemoglobinopathy characterized by ineffective erythropoiesis leading to reduced or absent β-globin chain synthesis, severe anemia and extensive erythroid expansion.
Each year thousands of infants are born afflicted with beta-thalassemia. Beta thalassemia is majorly prevalent in people from Mediterranean countries, North Africa, the Middle East, India, Central Asia, South Africa and Southeast Asia.
According to the ...
